0001209191-22-058183.txt : 20221121
0001209191-22-058183.hdr.sgml : 20221121
20221121165239
ACCESSION NUMBER: 0001209191-22-058183
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221121
FILED AS OF DATE: 20221121
DATE AS OF CHANGE: 20221121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lang Peter Frederick
CENTRAL INDEX KEY: 0001918982
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36152
FILM NUMBER: 221406434
MAIL ADDRESS:
STREET 1: AERIE PHARMACEUTICALS, INC.
STREET 2: 4301 EMPEROR BLVD., SUITE 400
CITY: DURHAM
STATE: NC
ZIP: 27703
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AERIE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001337553
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 203109565
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4301 EMPEROR BOULEVARD
STREET 2: SUITE 400
CITY: DURHAM
STATE: NC
ZIP: 27703
BUSINESS PHONE: (919) 237-5300
MAIL ADDRESS:
STREET 1: 4301 EMPEROR BOULEVARD
STREET 2: SUITE 400
CITY: DURHAM
STATE: NC
ZIP: 27703
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-21
1
0001337553
AERIE PHARMACEUTICALS INC
AERI
0001918982
Lang Peter Frederick
C/O AERIE PHARMACEUTICALS, INC.
4301 EMPEROR BLVD., SUITE 400
DURHAM
NC
27703
0
1
0
0
Chief Financial Officer
Common Stock
2022-11-21
4
D
0
46297
15.25
D
0
D
Stock Option (right to buy)
8.80
2022-11-21
4
D
0
160551
6.45
D
2032-03-18
Common Stock
160551
0
D
Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes.
Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration.
This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of August 22, 2022, by and among Aerie Pharmaceuticals, Inc. (the "Company"), Alcon Research, LLC (the "Parent"), and Lyon Merger Sub, Inc., a copy of which is filed as Exhibit 2.1 to the Company's Form 8-K filed with the SEC on August 23, 2022, pursuant to which the Company became a wholly owned subsidiary of Parent on November 21, 2022 (the "Effective Time").
/s/ John W. LaRocca, Attorney-In-Fact for Peter Frederick Lang
2022-11-21